PITTSBURGH -- (BUSINESS WIRE) -- Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, today announced that an analytical study evaluating the performance of the GeneFxTM Colon assay to identify high risk of recurrence for post-surgical stage II colon cancer patients has been accepted for publication by the journal Diagnostic Molecular Pathology (DMP).
Findings on the clinical validity of the 634-probe gene expression assay for identifying patients at risk of disease recurrence after surgery for stage II colon cancer were published in the Journal of Clinical Oncology in 2011.1 The GeneFxTM Colon assay used in the study has been clinically developed and validated using FFPE tissue from stage II colon cancer patients only. The assay has been validated to identify high risk patients at a level of significance that is superior to other FFPE tissue-based stage II colon cancer prognostic signatures.
The current study, titled, Analytical Performance of a Formalin-Fixed Paraffin-Embedded Tissue-Based 634-probe Prognostic Assay for Predicting Outcome of Patients with Stage II Colon Cancer, evaluated the analytical performance of the assay on FFPE tissue from a total of 52 stage II colon cancer patients from clinical centers and commercial tissue banks in Sweden, Ireland, Northern Ireland, Canada and the United States.
“The clinical significance of this study is that GeneFxTM Colon may have the ability to predict outcomes for patients with stage II colon cancer, enabling physicians to determine appropriate aggressiveness of treatment, depending on high or low risk of recurrence for their patients,” says Sean McDonald, President and CEO of Precision.
About GeneFxTM Colon
GeneFxTM Colon is a microarray-based gene signature developed for FFPE tissue from stage II colon cancer patients. GeneFxTM Colon is performed on a small amount of tissue, removed during surgery. This genomic signature identifies patients at higher risk of recurrence within 5 years following initial surgery. GeneFxTM Colon is expected to provide better-informed and more personalized treatment decisions.
About Precision Therapeutics
Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to utilizing precision medicine for personalized cancer care. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s leading products for personalized cancer care include:
Additionally, in 2013 Precision plans to release two new genomic products that examine a patients tumor at the molecular level in order to garner information about a patient’s individual disease and potentially inform effective treatment options, under the GeneFxTM brand. For more information, visit www.precisiontherapeutics.com.
1 Kennedy RD, Bylesjo M, Kerr P, Davison T Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol. 2011 Dec 10; 29(35):4620-6. Doi: 10.1200/JCO.2011.35.4498. Epub 2011 Nov 7. http://www.ncbi.nlm.nih.gov/pubmed/22067406